Nanobiotix Files Four New Patent Applications for Its Curadigm Platform
Nanobiotix has announced the filing of four new patent applications for its Curadigm nanoprimer platform, thereby expanding its intellectual property.
Strengthening Intellectual Property and Supporting Development
According to Nanobiotix's press release, the company has filed four new patent applications related to its Curadigm platform. These applications aim to strengthen the company's intellectual property, supporting both an internal product pipeline and external collaborations with the nanoprimer platform. Nanobiotix also unveiled in vivo preclinical data presented at the Partnership Opportunities in Drug Delivery (PODD) 2025 congress, which will serve as a foundation for the development of its first internal pipeline.
Material Transfer Agreements and Long-Term Growth Plans
The company has established several material transfer agreements with biopharmaceutical partners, thereby initiating collaborations to explore potential combinations with the Curadigm platform. Chemistry, manufacturing, and controls (CMC) activities have been launched to support this development. Nanobiotix plans to make Curadigm a cornerstone of its long-term growth by exploring various therapeutic applications, particularly in the oncology field.
Potential to Enhance Drug Delivery Beyond the Liver
Nanobiotix, specializing in nanoparticle-based therapeutic approaches, believes that the nanoprimer has the potential to push the boundaries of extra-hepatic distribution of intravenously administered therapeutic agents. Thanks to this technology, a greater fraction of administered drugs is expected to reach target tissues. The company, listed on Euronext Paris and the Nasdaq, intends to use these innovations to increase drug bioavailability while reducing off-target adverse effects.
